Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

The neuropathic pain market

Nature Reviews Drug Discovery volume 11, pages 101–102 (2012)Cite this article

Subjects

Current therapeutic options

Owing to the limited understanding of the precise aetiology of many neuropathic pain conditions, current pharmacological treatments encompass an array of drug classes including anticonvulsants, antidepressants, narcotic analgesics and topical anaesthetics. However, with just seven drugs approved for neuropathic pain conditions across the seven major markets (late 2011), and because of the limited efficacy of these drugs, off-label prescribing is widespread.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Shifting composition for the neuropathic pain market.

References

  1. Datamonitor. Epidemiology: Peripheral Neuropathic pain — A common co-morbidity for HIV, diabetes, and herpes zoster. HC00221–001 (October 2011)

  2. Datamonitor. R&D Trends: Neuropathic pain — Extensive and diverse pipeline driven by high unmet need. HC00064–006 (July 2011).

Download references

Author information

Authors and Affiliations

  1. Sarah Nightingale is an associate analyst at Datamonitor, 119 Farringdon Road, London EC1R 3DA, UK.,

    Sarah Nightingale

Authors
  1. Sarah Nightingale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Nightingale.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nightingale, S. The neuropathic pain market. Nat Rev Drug Discov 11, 101–102 (2012). https://doi.org/10.1038/nrd3624

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3624

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research